Prostatic Neoplasms Clinical Trial
— VITALITEOfficial title:
Contributions of a Paramedical Approach in the Prevention and Treatment of Side Effects Associated With Radical Prostatectomy (RP): "Vitality", an Onco-sexology Program
The paramedic urology team at Martinique University Hospital has developed a "personalized rehabilitation oncosexology program for patients undergoing radical prostatectomy (RP) for localized prostate cancer". The aim of this project is to assess the effectiveness of this program by comparing the sexual quality of life 1 year after surgery between patients participating and those who do not.
Status | Recruiting |
Enrollment | 136 |
Est. completion date | March 31, 2025 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men diagnosed with localized prostate cancer and consulting in the urology department of Mangot Vulcin site of the Martinique University Hospital - Patients newly diagnosed for prostate cancer and who will benefit from radical prostatectomy (regardless the technique : laparotomy, laparoscopy or robot-assisted micro-invasive surgery) - Fluent in French or Creole - Patients who give consent - Patients affiliated to social security Exclusion Criteria: - Patients diagnosed with another tumor - Person under legal protection |
Country | Name | City | State |
---|---|---|---|
Martinique | Centre Hospitalier Universitaire de Martinique | Fort-de-France |
Lead Sponsor | Collaborator |
---|---|
University Hospital Center of Martinique |
Martinique,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of sexual Quality of Life: Questionnaire | Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) | Before the radical prostatectomy | |
Primary | Evaluation of sexual function: Questionnaire | Administration of sexual function questionnaire (IIEF-type validated questionnaires) | Before the radical prostatectomy | |
Primary | Evaluation of sexual Quality of Life: Questionnaire | Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) | 1 Month after the radical prostatectomy | |
Primary | Evaluation of sexual function: Questionnaire | Administration of sexual function questionnaire (IIEF-type validated questionnaires) | 1 Month after the radical prostatectomy | |
Primary | Evaluation of sexual Quality of Life: Questionnaire | Administration of sexual of life questionnaire (SEAR for self-esteem and couple relationship) | 12 months after the radical prostatectomy | |
Primary | Evaluation of sexual function: Questionnaire | Administration of sexual function questionnaire (IIEF-type validated questionnaires) | 12 months after the radical prostatectomy | |
Secondary | Evaluation of quality of life in its multidimensional aspect | Administration of quality of life questionnaire (EORTC QLC C30 questionnaires) | Before the radical prostatectomy | |
Secondary | Evaluation of quality of life for localized forms of prostate cancer | Administration of QLQ-PR25 questionnaire (specific module intended for localized forms of prostate cancer. It is complementary to QLQ-C30 and better suited to measure the side effects of treatment.) | Before the radical prostatectomy | |
Secondary | Evaluation of quality of life in its multidimensional aspect | Administration of quality of life questionnaire (EORTC QLC C30 questionnaires) | 12 Month after the radical prostatectomy | |
Secondary | Evaluation of quality of life for localized forms of prostate cancer | Administration of QLQ-PR25 questionnaire ((specific module intended for localized forms of prostate cancer. It is complementary to QLQ-C30 and better suited to measure the side effects of treatment.) | 12 Month after the radical prostatectomy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |